Aclaris Publishes ATI-052 Phase 1b Results Presentation
Aclaris Therapeutics published a presentation of ATI-052 Phase 1b results in atopic dermatitis and asthma.
Related stories
X2M Connect Secures A$1.4M for Data Centre and AI Strategy
M impact | EQUITY | Oct 30, 2026, 01:21 AM UTC
X2M Connect Secures A$1.4 Million for Data Centre and AI Strategy
M impact | EQUITY | Oct 30, 2026, 01:21 AM UTC
Zhongji Innolight Hong Kong shares open 7.2% lower, hit record low
Hong Kong-listed Zhongji Innolight shares opened 7.2% lower, reaching their lowest level since listing.
M impact | EQUITY | Oct 30, 2026, 01:21 AM UTC
X2M Connect Reports Q1 FY27 Revenue of A$1.4 Million
X2M Connect posted revenue of A$1.4 million for Q1 FY27.
M impact | EQUITY | Oct 30, 2026, 01:20 AM UTC
OncoSil Medical Q1 FY27 Sales Revenue Rises 45.8% Year On Year
M impact | EQUITY | Oct 30, 2026, 01:20 AM UTC
Xreality Group Posts Quarterly Annual Recurring Revenue of A$8.8 Million
M impact | EQUITY | Oct 30, 2026, 01:20 AM UTC